Clinical trial · no report yet · Phase 2
NCT05411081
Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial
- NCT05411081 ↗
- Active not recruiting
- National Cancer Institute (NCI)
- 60 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 30 | |
| YouTube | 20 | |
| Podcasts | 9 | |
| X videos | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase II Randomized Trial of Cabozantinib (NSC #761968) With or Without Atezolizumab (NSC #783608) in Patients With Advanced Papillary Renal Cell Carcinoma (PAPMET2)
- Phase
- Phase 2
- Status
- Active not recruiting
- Conditions
- Metastatic Papillary Renal Cell Carcinoma; Stage IV Renal Cell Cancer AJCC v8
- Interventions
- Atezolizumab; Biospecimen Collection; Bone Scan; Cabozantinib S-malate; Computed Tomography; Magnetic Resonance Imaging
- Arms
- Arm I (cabozantinib S-malate) · Active comparator
- Arm II (cabozantinib S-malate, atezolizumab) · Experimental
- Enrollment
- 200 (estimated)
- Primary outcomes
- Progression free survival
- Sponsor
- National Cancer Institute (NCI)
- Start
- Mar 24, 2023
- Primary completion
- Jul 1, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05411081 · updated Oct 1, 2026